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Abstract. Liver metastasis in colorectal cancer is common and 
the primary treatment is chemotherapy. To date, there is no 
routinely used test in clinical practice to predict the effective-
ness of conventional chemotherapy. Therefore, biomarkers with 
predictive value for conventional chemotherapy would be of 
considerable benefit in treatment planning. We analysed three 
proteins [excision repair cross-complementing 1 (ERCC1), 
ribonucleoside-diphosphate reductase 1 (RRM1) and class III 
β-tubulin (TUBB3)] in colorectal cancer liver metastasis. 
We used tissue microarray slides with 101 liver metastasis 
samples, stained for ERCC1, RRM1 and TUBB3 and estab-
lished scoring systems (fitted for tissue microarray) for each 
protein. In statistical analysis, we compared the expression of 
ERCC1, RRM1 and TUBB3 to mismatch proteins (MLH1, 
MSH2, MSH6 and PMS2), p53 and to apoptosis repressor 
protein (ARC). Statistically significant correlations were found 
between ERCC1, TUBB3 and MLH1, MSH2 and RRM1 and 
MSH2, MSH6. Noteworthy, our analysis revealed a strong 
significant correlation between cytoplasmic ARC expression 
and RRM1, TUBB3 (p=0.000 and p=0.001, respectively), 
implying an additional role of TUBB3 and RRM1 not only 
in therapy resistance, but also in the apoptotic machinery. 
Our data strengthens the importance of ERCC1, TUBB3 and 
RRM1 in the prediction of chemotherapy effectiveness and 
suggest new functional connections in DNA repair, microtu-
bule network and apoptotic signaling (i.e. ARC protein). In 
conclusion, we showed the importance and need of predictive 
biomarkers in metastasized colorectal cancer and pointed out 
the relevance not only of single predictive markers but also of 
their interactions with other known and newly explored rela-
tions between different signaling pathways.
Introduction
Colorectal cancer (CRC) remains a leading cause of cancer-
associated deaths worldwide with an incidence of over one 
million newly diagnosed cases per year. Despite intensive 
research and therapeutic efforts, the mortality rate of CRC 
is ~40-50% (1). Furthermore, the rate of metastatic cases is 
high (2). Drug resistance is responsible for poor prognosis in 
many cancer types (3). Thus, to identify proteins which may 
have predictive value is of importance not only in metasta-
sized CRC, but also in other advanced epithelial cancers. In 
this regard, the deregulation of DNA damage repair systems 
(i.e. mismatch repair) represents an important aspect, since it 
contributes to the resistance of cancer cells to conventional 
chemotherapy.
One further repair protein is excision repair cross-
complementing 1 (ERCC1), which is also implicated in 
therapy resistance. ERCC1 is a structure specific DNA repair 
endonuclease responsible for 5' incision (5'-endonuclease), a 
key enzyme in the nucleotide excision repair (NER) pathway 
and is essential for repair of platinum-DNA adducts, and is 
thus associated with therapy resistance to platinum-containing 
compounds (3,4). NER is responsible for repair of DNA 
damages caused by oxidative and alkylating agents (3). 
ERCC1 was suggested as a promising marker in CRC (4). 
ERCC1-overexpressing cancer cells are thought to be more 
resistant to platinum-based chemotherapy. Increased ERCC1 
mRNA levels were found to be associated with resistance to 
platinum-based chemotherapy (i.e. ovarian, gastric, cervical, 
colorectal and non-small cell lung cancer) suggesting that 
platinum-paclitaxel chemotherapy would be more effective in 
ERCC1-negative cancer (3). It is known that ERCC1 protein 
expression, estimated by immunohistochemistry, is an inde-
pendent prognostic factor for progression-free and overall 
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survival in NsCLC patients treated with platinum-based 
chemotherapy (5). Similar data could be achieved in CRC (6). 
In several trials on CRC, the ERCC1 expression level was 
proposed as a candidate marker for predicting the efficacy of 
oxaliplatin therapy for metastatic patients. In stage III colon 
cancer, ERCC1 expression is strongly predictive in the selec-
tion of patients which will benefit from additional oxaliplatin 
to 5-fluorouracil (5-FU) therapy (7).
Ribonucleoside-diphosphate reductase 1 (RRM1) gene 
encodes the regulatory subunit of ribonucleotide reductase 
enzyme. Ribonucleotide reductase, composed of regulatory 
subunit RRM1 and the catalytic subunit RRM2, is a crucial 
enzyme in new DNA synthesis, catalysing the biosynthesis 
of deoxyribonucleotides from the corresponding ribonucleo-
tides (8). RRM1 is a key molecule for gemcitabine efficacy and 
is also involved in tumor progression. High RRM1 expression 
in tumor tissue predicts significantly better prognosis while 
only patients with low RRM1 benefit from gemcitabine 
therapy. In turn, overexpression of RRM1 protein is strongly 
associated with gemcitabine resistance (8). RRM1 expression 
was also reported to correlate with the tumorigenic and meta-
static potential in lung cancer (8).
The cell cytoskeleton is built up from microtubules, micro-
filaments and intermediate filaments. Various changes in the 
microtubule network have been identified in a wide range of 
cancers, i.e. altered expression of tubulin isotypes, alterations 
in tubulin posttranslational modifications and changes in the 
expression of microtubule-associated proteins (MAPs) (9). 
Class III β-tubulin (TUBB3) is one of the main microtu-
bule (MT) proteins and is primarily expressed in neurons and 
Sertoli cells in the testis (10,11). In lung cancer, the TUBB3 
protein expression level was found to have no correlation with 
age, gender, smoking status or recurrence pattern or response 
rate to chemotherapy. The response rate in TUBB3-positive 
cases was 18%, while the rate was 27% in negative cases (no 
significant differences could be detected) (5). High TUBB3 
expression levels are associated with poor prognosis in many 
epithelial cancers. Additionally, TUBB3 has been suggested to 
take part in disease aggressiveness by acting as a survival factor 
for cancer cells (12). In colorectal adenomas, TUBB3 expres-
sion can be detected in up to 100% of high-grade dysplasia. 
Expression of TUBB3 was found to have no association with 
grade of dysplasia or other clinical data in preneoplastic lesions 
of CRC but was associated with Dukes' stage (13). TUBB3 
overexpression in colon cancer cells may contribute to a higher 
stability of the microtubular network which may explain the 
lower activity of anti-microtubule agents (14). In addition, high 
TUBB3 expression levels were localized to the invasive edge in 
CRC; positive TUBB3 staining was observed in all cases, yet this 
was most prominent at the invasive front with the presence of 
tumor budding (12). This preferential localization of TUBB3 at 
the invasive margin raises the possibility that changes in tubulin 
isotypes can modulate the invasive activity of cancer cells. 
Microtubules are indispensable for the directional migration of 
cells. Tubulins, the major constituent protein of microtubules, 
are built up from heterodimers of α and β subunits (12). It is 
believed that tumor buds consist of migrating cells and TUBB3 
expression in these cells is linked to their motility. Furthermore, 
TUBB3 is expressed in a variety of tumors, particularly in 
those that are aggressive and likely to metastasize, and were 
found to be more resistant to several chemotherapy regimens 
(i.e. estramustine, Taxol, paclitaxel and docetaxel) (12). As we 
previously demonstrated, MMR protein expression is correlated 
with the expression of the apoptosis repressor protein apoptosis 
repressor protein (ARC). It is known that overexpression of 
ERCC1, RRM1 and TUBB3 is linked to therapeutic resistance 
against therapeutic regimens, which is also found in advanced 
(stage IV) CRC (15). In this context, we investigated the expres-
sion trend of ERCC1, RRM1 and TUBB3 proteins and their 
correlation to ARC protein expression, which is known to be 
upregulated in CRC and associated with therapeutic resistance 
inhibiting both extrinsic and intrinsic apoptotic signaling.
Materials and methods
Tissue samples. Paraffin-embedded surgical specimens of 
liver metastasis of CRC were selected from the archives of the 
Institute of Pathology at the University Hospital of Heidelberg. 
One hundred patients (64 male, 37 female; mean age 62 years) 
were included. None of the patients had received neo-adjuvant 
chemotherapy. Tissue samples were fixed in neutral-buffered 
formalin and embedded in paraffin. Paraffin sections were cut 
(4 µm) and examined on coated slide glass for immunohis-
tochemistry. Further data, such as age, sex, size and number 
of metastases were collected from histological studies. Tissue 
samples were provided by the Tissue Bank of the National 
Center for Tumor Diseases (NCT, Heidelberg, Germany) in 
accordance with the regulations of the tissue bank and the 
approval of the Ethics Committee of Heidelberg University 
according to ethical standards formulated in the Declaration 
of Helsinki 1975 (revised in 1983).
Tissue microarray. Tissue microarray (TMA) blocks were 
obtained from paraffin-embedded human liver specimens 
with a tissue microarrayer (Beecher Instruments, Sun Prairie, 
WI, USA). From each case, two cores of tumor tissue with a 
diameter size of 1.6 mm were punched and for orientation of 
the TMA slides two muscle cores were used. Muscle punches 
served also as positive controls for ARC immunostaining.
Immunohistochemistry. Four-micrometer-thick slides were 
obtained from the TMA. slides were then deparaffinised 
according to standard protocol by xylene, and dehydrated with 
95-96% ethanol, 70% ethanol and distilled water. All slides 
were stained simultaneously using a computer-controlled 
autostainer (Ventana BenchMark Ultra, Ventana Medical 
Systems, Inc., Tucson, Az, USA). Then primary antibodies 
were used: ERCC1 (8F1, Neomarkers; dilution 1:100), 
RRM1 (Protein Tech Europe; dilution 1:200) and TUBB3 
(Tuj-1/TubIII/4G3, Covalab; dilution 1:2,000). Primary anti-
bodies were incubated according to routine staining protocols 
for diagnostic purpose. To detect immunoreactions, Ultraview 
Universal DAB dectection kit (Ventana Medical Systems, Inc.) 
and 3,3'-diaminobenzidine were used. A counterstain was 
performed with hematoxylin and bluing reagent and all slides 
were covered. For MMR proteins, p53 and ARC, the staining 
methods were performed as previously published (16).
Evaluation of immunohistochemistry. For semi-quantitative 
assessment of staining intensity, we adjusted a previously 
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published scoring system for each protein and fitted to TMA 
dots (17,18). ERCC1 and RRM1 immunostainings were scored 
using a three-graded scale: score 0, no expression detectable 
or faint partial expression in <10% of the tumor cells; score 1, 
weak to moderate expression of the entire tumor tissue; 
score 2, strong positivity in the entire tumor tissue.
For TUBB3, a modified three-graded score was established: 
score 0, no expression detectable or faint partial expression in 
<10% of the tumor cells; score 1, diffuse and strong positive 
staining associated to invasive front and tumor budding, central 
tumor regions negative or with weaker intensity than at the inva-
sive front; score 2, strong positivity in the entire tumor tissue.
For MSI proteins, the staining was evaluated according to 
Bethesda guidelines (19). Immunostaining for p53 was scored 
using a three-graded scale: score 0, weak staining in <10% of 
the tumor cells, score 1, moderate staining in up to 75% of the 
tumor cells and score 2, strong nuclear staining in >75% of the 
tumor cells. The results of MMR, p53 and ARC immunohisto-
chemistry for this collective have already been published (16).
The immunostained tissue microarray sections were evalu-
ated and scored under a light microscope independently by 
two pathologists in a blinded manner. Discordant cases were 
reviewed and re-evaluated based on a consensus opinion.
Statistical analysis. The statistical analyses were performed 
with SAS software (SAS Institute, Cary, NC, USA). 
Associations between clinical data, ARC, MMR proteins, 
ERCC1, TUBB3 and RRM1 were estimated by Pearson's 
correlation and linear regression test. The statistical signifi-
cance was set at p<0.05 and p<0.01.
Results
Distribution of ERCC1, RRM1 and TUBB3 protein expression 
in the collective. The results of the immunohistochemistry for 
ERCC1, RRM1 and TUBB3 are listed in Table I. For ERCC1 
we found 29.8% of the cases to be negative (score 0). Positive 
ERCC1 staining was detected in 70.2% of the cases (score 1, 
30.8% and score 2, 39.4%). For RRM1, the distribution was 
different. Only 11 cases out of 95 valid cases (11.6%) were 
found to be negative (score 0). Eighty-four cases (88.4%) 
showed positive staining for RRM1, 51 cases showed a high 
expression level (score 2, 53.7%).
TUBB3 staining showed an interesting distribution. Most 
of the cases showed pronounced positivity at the invasive 
margin (52%). Thirty-five cases (35%) had negative staining 
and only 13% had a diffuse positive staining reaction for 
TUBB3. Representative images of the staining scores for 
ERCC1, RRM1 and TUBB3 are shown in Figs. 1-3.
Table I. Results of the immunohistochemistry for ERCC1, RRM1 and TUBB3.
 Immunoreactive score 0 Immunoreactive score 1 Immunoreactive score 2 Valid cases
Proteins n (%) n (%) n (%) n (%)
ERCC1 28 (29.8) 29 (30.8) 37 (39.4) 94 (100)
RRM1 11 (11.6) 33 (34.7) 51 (53.7) 95 (100)
TUBB3 35 (35) 52 (52) 13 (13) 100 (100)
ERCC1, excision repair cross-complementing 1; RRM1, ribonucleoside-diphosphate reductase 1; TUBB3, class III β-tubulin.
Figure 1. Representative examples of the expression of excision repair cross-
complementing 1 (ERCC1) protein in colorectal liver metastasis. (A) Score 0, 
no expression detectable or faint partial expression in <10% of the tumor cells; 
(B) score 1, weak to moderate expression of the entire tumor tissue; (C) score 2, 
strong positivity in the entire tumor tissue; magnification, x400.
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Statistically significant correlation between ERCC1, RRM1, 
TUBB3 and MMR proteins, but not with p53. Regarding MMR 
proteins we found statistically significant correlations between 
MMR proteins and ERCC1, RRM1 and TUBB3. In turn, none 
of the three markers demonstrated a correlation with the p53 
expression level. MLH1 and MSH2 proteins showed a positive 
statistically significant correlation with ERCC1 (p<0.000 and 
p=0.008, respectively). This means that loss of MLH1 and 
MSH2 is associated with lower expression or loss of ERCC1 in 
colorectal liver metastasis. A similar correlation was detected 
between MSH2, MSH6 and RRM1 (p=0.005 for MSH2 and 
p=0.011 for MSH6). Higher RRM1 expression levels were 
detected at intact expression of MSH2 and MSH6.
Notably, TUBB3 expression showed a strong positive 
correlation with MLH1 and MSH2 (p=0.019 and p=0.012, 
respectively). The detailed correlations are documented in 
Table II.
Cytoplasmic ARC staining intensity is strongly correlated 
with TUBB3 and RRM1 expression levels. In negative 
RRM1 cases, the ARC cytoplasmic expression was also low 
(score 0/1) (6/10, 60%). Cases with moderate RRM1 expression 
(score 1) also had in the majority of cases a low level of ARC 
expression (19/33, 57.6%). Fourteen of 33 cases (42.4%) with 
moderate RRM1 expression had a high level of cytoplasmic 
ARC (score 2/3). Cancers expressing RRM1 at high levels 
(score 2, 51 cases) showed, in the majority of cases, elevated 
cytoplasmic ARC levels [low ARC level in only 12 cases 
Figure 2. Representative examples of the expression of ribonucleoside-diphos-
phate reductase 1 (RRM1) protein in colorectal liver metastasis. (A) Score 0, 
no expression detectable or faint partial expression in <10% of the tumor cells; 
(B) score 1, weak to moderate expression of the entire tumor tissue; (C) score 2, 
strong positivity in the entire tumor tissue; magnification, x400.
Figure 3. Representative examples of the expression of class III β-tubulin 
(TUBB3) protein in colorectal liver metastasis. (A) Score 0, no expression 
detectable or faint partial expression in <10% of the tumor cells; (B) score 1, 
diffuse and strong positive staining associated to invasive front and tumor 
budding, central tumor regions negative or with weaker intensity then at 
the invasive front; (C) score 2, strong positivity in the entire tumor tissue; 
magnification, x400.
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(12/51, 23.53%), high ARC level in 39 cases (39/51, 76.47%)]. 
In conclusion, a high level of RRM1 expression in most of 
the cases occurred simultaneously with elevated, high level 
cytoplasmic ARC protein expression (score 2/3 in 76.47% of 
the valid cases). Cytoplasmic ARC protein expression showed 
a positive, statistically significant correlation with RRM1 
expression levels (p<0.000). Ninty-eight cases were valid for 
both proteins (ARC cytoplasmic and TUBB3). In TUBB3 
negative cases (score 0), cytoplasmic expression of ARC was 
detected in 15 cases (15/35, 42.85%). In TUBB3 score 1 cases, 
it was even higher (35/51, 68.62%). In strongly diffuse positive 
TUBB3 cases, the highest cytoplasmic ARC expression was 
found (9/12, 75%). We found a progressive staining intensity 
for cytoplasmic ARC regarding TUBB3 status. This asso-
ciation was also significant (p<0.001). The distribution of the 
statistical results is listed in Table III.
Correlations between ERCC1, RRM1, TUBB3 and clinical 
data. Concerning clinical parameters such as age, sex of 
the patients, grade of the tumor and the number and size of 
metastases, there was no significant correlation with ERCC1 
or RRM1 expression (Table IV). Regarding patient age, there 
Table II. Statistical correlations between ERCC1, RRM1 and TUBB3 with mismatch repair proteins and p53.
Protein MLH1 MSH2 MSH6 PMS2 p53
ERCC1
  Correlation coefficient 0.541a 0.273a 0.186 0.168 0.164
  Significance (2-sided) 0.000 0.008 0.072 0.106 0.116
  No. of valid cases 71 94 94 94 93
RRM1
  Correlation coefficient 0.104 0.283a 0.261b 0.198 0.146
  Significance (2-sided) 0.387 0.005 0.011 0.055 0.160
  No. of valid cases 71 95 95 95 94
TUBB3
  Correlation coefficient 0.271b 0.252b 0.025 0.033 0.035
  Significance (2-sided) 0.019 0.012 0.808 0.748 0.736
  No. of valid cases 75 99 99 99 98
aThe correlation is significant at the level of 0.01 (2-sided); bThe correlation is significant at the level of 0.05 (2-sided). ERCC1, excision repair 
cross-complementing 1; RRM1, ribonucleoside-diphosphate reductase 1; TUBB3, class III β-tubulin.
Table III. Results of the statistical analysis between apoptosis 
repressor ARC protein and ERCC1, RRM1 and TUBB3.
  Cytoplasmic ARC Nuclear ARC
Protein expression expression
ERCC1
  Correlation coefficient -0.053 -0.020
  Significance (2-sided) 0.613 0.851
  Number of valid cases 93 93
RRM1
  Correlation coefficient 0.378a 0.147
  Significance (2-sided) 0.000 0.156
  Number of valid cases 94 94
TUBB3
  Correlation coefficient 0.323a -0.048
  Significance (2-sided) 0.001 0.641
  Number of valid cases 98 98
aThe correlation is significant at the level of 0.01 (2-sided); bThe cor-
relation is significant at the level of 0.05 (2-sided). ERCC1, excision 
repair cross-complementing 1; RRM1, ribonucleoside-diphosphate 
reductase 1; TUBB3, class III β-tubulin.
Table IV. Results of the statistical analysis between ERCC1, 
RRM1 and TUBB3 and clinical data.
   Tumor No. of 
Protein Age Sex grade metastases
ERCC1
  Correlation coefficient 0.106 -0.205 -0.010 -0.030
  Significance (2-sided) 0.320 0.054 0.930 0.781
  No. of valid cases 90 89 82 86
RRM1
  Correlation coefficient 0.004 0.001 0.151 0.027
  Significance (2-sided) 0.971 0.995 0.174 0.803
  No. of valid cases 91 90 83 87
TUBB3
  Correlation coefficient -0.269a -0.139 0.213b 0.026
  Significance (2-sided) 0.008 0.178 0.047 0.807
  No. of valid cases 96 95 87 92
aThe correlation is significant at the level of 0.01 (2-sided); bThe cor-
relation is significant at the level of 0.05 (2-sided). ERCC1, excision 
repair cross-complementing 1; RRM1, ribonucleoside-diphosphate 
reductase 1; TUBB3, class III β-tubulin.
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was a strong negative correlation with TUBB3 expression level 
(p=0.008). In addition, the TUBB3 expression level was also 
positively associated with tumor grade (p=0.047) and TUBB3 
expression was also correlated with the RRM1 expression 
level (p=0.022).
Discussion
Apoptotic signaling is one of the most important processes 
in therapeutic resistance. In addition to known regulatory 
proteins, there are many others, which can influence the 
apoptotic process, and some can thus enhance or inhibit 
therapeutic effects. ERCC1, RRM1 and TUBB3 are known 
to have therapeutic predictive value in the current therapy of 
metastasized CRC (3,5,6). In the present study, we investigated 
the expression levels of ERCC1, RRM1 and TUBB3 in liver 
metastasis of CRC and analysed their associations to sex, age, 
tumor grade, mucin production, tumor size and number of 
metastases. Furthermore, we investigated their correlation to 
MMR proteins, p53 and apoptosis repressor ARC.
In our collective, ERCC1 protein loss was detected in one-
third of the cases (29.8%). A proportion of 70.2% showed a 
positive reaction and score 2 (strong nuclear expression) was 
confirmed in 39.4% of all valid cases. In another study, which 
investigated stage III CRC, ERCC1 and MSI levels were found 
to be positive in 55 and 17%, respectively (7). According to 
literature data, score 2 cases do not benefit from platinum-
based chemotherapy. On the other hand, one-third of cases (loss 
of ERCC1) have a better prognosis following platinum-based 
chemotherapy (15). Cases with moderate ERCC1 expression 
(score 1), in our opinion, require further investigation. It must 
be evaluated in functional studies, whether a mild loss in 
ERCC1 expression is enough to sensitize cancer cells to plat-
inum-based chemotherapy. According to our scoring system, 
we detected certain negative and positive cases, thus allowing 
a prediction for platinum-based chemotherapy in two-thirds of 
the patients after a single immunohistochemistry.
We found a statistically significant positive correlation 
between ERCC1 and MLH1, MSH2 (p=0.000 and p=0.008, 
respectively). The frequent loss of ERCC1 and MLH1 both 
could be explained by methylation. similar correlations were 
found in mesothelioma (20). In NSCLC, ERCC1 nuclear 
staining was noted in 45.59% of the cases, and TUBB3 cyto-
plasmic staining was noted in 65.44% of the cases detected. 
ERCC1 and TUBB3 double-negative cases exhibited a better 
therapeutic response to platinum-based therapy (3). We found 
11 cases (11.7% of valid cases) as double-negative for ERCC1 
and TUBB3. Analogous to other epithelial neoplasia, 11.7% of 
the metastatic cases could benefit much more from platinum-
based therapy, than the others. Negative expression of ERCC1 
and TUBB3 was found to be associated with a significantly 
higher response rate, longer median progression-free survival 
and overall survival after platinum-paclitaxel treatment (3). 
One study found that patients with advanced CRC with high 
expression of ERCC1 are not indicated for oxaliplatin-based 
chemotherapy (17), whereas patients with low levels of 
ERCC1 expression have been reported to have an improved 
response and a longer overall survival in metastatic CRC 
treated with FOLFOx combination (18). In this study, a low 
level of ERCC1 was detected in 90% of the cases (18). One 
study, in accordance with other study results, demonstrated 
the potential utility of ERCC1 expression as a prognostic and 
possibly predictive biomarker in metastasized CRC. It was 
able to identify a population with poor prognosis, as well as 
a population with a markedly high response rate to FOLFOx 
combination therapy (18). The cases were evaluated according 
to a pre-established cut-off for ERCC1 (17). As noted, the 
expression levels of ERCC1 are not always consistent with 
sensitivity to platinum-based treatment. We assume that the 
cut-off level was set too high and suggest to define more than 
only two groups (positive and negative). Therefore, we propose 
the use of large prospective or retrospective studies with 
standard chemotherapy to analyse the expression of predictive 
markers, such as ERCC1, RRM1 or TUBB3 (and its interac-
tion partners) to set a cut-off for cases, which can benefit from 
a therapeutic regimen. Too high or too low cut-off levels result 
in subsets of patients, who may suffer from long-term toxicity 
with no benefit of treatment, and patient groups that do not 
receive the optimal therapy regimen.
RRM1 overexpression is associated with gemcitabine resis-
tance. RRM1 is a key molecule for gemcitabine efficacy and 
is also involved in tumor progression. High RRM1 expression 
in tumor tissue predicts significantly better prognosis, whereas 
only patients with low RRM1 benefit from gemcitabine therapy. 
In turn, overexpression of RRM1 protein is strongly associated 
with gemcitabine resistance (8). RRM1 expression was also 
reported to correlate with tumorigenic and metastatic potential 
in lung cancer (8). According to our data, only 11.6% of the 
cases with loss of RRM1 expression had a positive response to 
gemcitabine. In other words, patients with high RRM1 protein 
expression in tumor tissue should be treated with alternative 
drugs, i.e. oxaliplatin, 5-FU and leucovorin (CONkO-003) 
instead of gemcitabine (8). As mentioned above, score 1 cases 
need further functional analysis and lower RRM1 activity may 
also be sufficient not to overcome gemcitabine-induced DNA 
damage leading to the death of tumor cells.
Loss of MSH2 and MSH6 expression is associated with 
lower levels of RRM1 protein (p=0.005 and p=0.011, respec-
tively). For this association the following mechanisms could 
be responsible: i) RRM1 is a key enzyme in the synthesis of 
new DNA, thus defected MMR proteins, i.e. MSH2 and MSH6 
lead to DNA damage which can downregulate the new DNA 
synthesis, leading to cell cycle arrest. One possible connection 
between RRM1 and the MMR system is through DNA damage. 
It leads to cell cycle arrest, which results in lower RRM1 
expression level or ii) there is a possible connection through 
transforming growth factor-β (TGF-β); in normal cells TGF-β 
can activate the MSH2 promoter (through Smad p53 dependent 
mechanism), whereas at the posttranscriptional level, miR-21 
induced by TgF-β targets MSH2 transcript and suppresses 
its expression. In contrast, in cancer cells p53 is inactivated 
and miR-21 is overexpressed, thus TgF-β fails to activate the 
MSH2 promoter resulting in genomic instability (21).
Cytoplasmic ARC protein expression showed a positive, 
statistically significant correlation with RRM1 expression 
levels (p<0.000). Which mechanism leads to higher RRM1 
expression with ARC overexpression or in turn how ARC 
expression can induce RRM1 overexpression should be 
elucidated in functional studies, but it is known that RRM1-
overexpressing cells have an increased level of apoptosis (22), 
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thus it is possible that a certain overexpression level can induce 
apoptotic signaling, which in turn induces ARC expression 
to suppress apoptosis induction. This possibility is further 
strengthened by the positive correlation between RRM1 and 
TUBB3 found in our collective (p=0.022).
The main staining pattern for TUBB3 was expression 
at the invasive front, similar to primary CRC studied previ-
ously (12). TUBB3 expression was not detected in 35% of the 
valid cases. These cases are potential candidates for taxane-
based chemotherapy with highly predicted response. In our 
Figure 5. Interactions between tubulins and apoptotic signaling proteins including apoptosis repressor protein (ARC). 
Figure 4. Schematic presentation of DNA damage-induced apoptosis and the possible role of the microtubule system. 
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collective, we found a statistically significant correlation 
between MLH1, MSH2 and TUBB3 (p=0.019 and p=0.012, 
respectively), which further strengthens the evidence of the 
regulatory role of mismatch repair proteins in apoptosis. In 
the case of sufficient MLH1 and MSH2 expression, TUBB3 
is significantly highly expressed to suppress the activities of 
MLH1 and MSH2.
These results can indicate that a defected MMR system 
would induce TUBB3 overexpression leading to MT rear-
rangement, which can influence apoptosis (i.e. activating 
pro-apoptotic signaling proteins). Microtubules (MTs) have an 
important role in apoptosis, i.e. survivin is believed to regulate 
apoptosis by controlling microtubule polymerization. Thus, 
the disruption of normal MT function (either increasing or 
decreasing MT length) may trigger apoptosis. MT system (and 
thus TUBB3) has an important role in the regulation of DNA 
damage-induced apoptosis. DNA damage (i.e. γ-radiation) 
induces α-, β- and γ-tubulin production and polymerization, 
and stimulates MT reorganization (23). One explanation is that 
DNA damage through cyclin B1 and cdc2 kinase activation 
leads to tubulin polymerization and to release of apoptosis (23). 
The possible connection between TUBB3, DNA damage and 
mismatch repair are depicted in Fig. 4. After DNA damage, 
the ATM/ATR signaling pathway is activated and phosphory-
lates (and activates) Chk1 and Chk2, which subsequently 
phosphorylate cdc25 (23). Phosporylated cdc25 is sequestered 
in the cytoplasm by 14-3-3 proteins, which hinder the activa-
tion of cyclin B1/Cdk1 complex by cdc25 resulting in G2/M 
cell cycle arrest. In the case of MMR loss (i.e. in our cases, 
the loss of MLH1 and MSH2) the ATM/ATR system cannot 
be activated by MMR proteins and finally do not lead to cell 
cycle arrest. Consequently, microtubule rearrangement and 
TUBB3 upregulation is lacking. This correlation between 
MLH1/MSH2 and TUBB3 was statistically significant in our 
collective (p=0.019 and p=0.012, respectively).
Furthermore, MLH1 and MSH2 are responsible for resis-
tance to cisplatin or methylating agents. The defective MMR 
system cannot recognize the cisplatin-induced DNA damage 
resulting in cell survival and therapeutic resistance (24,25). 
Taken together, cases with defected MMR system (micro-
satellite instable cancer) and with a high expression level of 
TUBB3 are potentially resistant not only to taxanes, but also 
to platinum-based therapy. Thus, we favor, in the case of MsI, 
immunohistochemical testing also for TUBB3 to exclude 
taxane resistance. The interactions between DNA repair 
systems, MT and apoptotic proteins (i.e. ARC) should be 
further investigated to elucidate the resistance mechanism of 
tumor cells and the survival regulatory mechanism.
In addition and alternatively to the above mentioned 
mechanisms, the statistically significant correlation between 
TUBB3 and cytoplasmic ARC expression (p=0.001) can also 
be explained. survival feedback mechanism can induce ARC 
expression to suppress pro-apoptotic signaling, thus cancer 
cells can survive despite of DNA damage (i.e. microsatellite 
instability). In our previous study, we found a strong corre-
lation between ARC expression level and MSH2 status (16). 
TUBB3 overexpression can stabilize the MT system and 
make cancer cells resistant against anti-microtubule agents. 
Direct interaction between tubulin with several members of 
the Bcl-2 family has been described. Bcl-2, Bid and Bad were 
found to inhibit the assembly, whereas Bak and Bax promote 
tubulin polymerization. Thereby, tubulin is localized not only 
in the cytoplasm, but also binds to mitochondria (associated 
with VDAC in mitochondrial membrane). Both pro- and anti-
apoptotic proteins bind to tubulin and those of lower affinity 
are more easily released following a conformational change 
induced by a ligand. Thus, Bcl-2, Bid and Bad may remain 
bound, while Bax would be released changing the ratio of free 
pro- and anti-apoptotic proteins. Furthermore, in the case of 
TUBB3 overexpression pro- and anti-apoptotic proteins stay 
bound, but tubulin ligands can change the affinity towards 
proteases. In addition, Bcl-2 protects against acetylation of 
tubulin and Bcl-2 is able to normalize the level of acetylated 
tubulin (26). The interaction between TUBB3 and apoptotic 
proteins (especially between ARC and TUBB3) seems to be 
more complex. There are many common interaction partners 
of ARC and TUBB3 and which protein effects will dominate 
depends on intracellular circumstances. The known interac-
tions between apoptotic proteins, including ARC and TUBB3 
are depicted in Fig. 5. Despite the increasing number of studies 
that highlight the importance of TUBB3 in tumor cells, its 
mode of action still needs to be fully determined. It appears 
that the intrinsic apoptotic pathway is involved as evidenced 
by increased caspase-3/7 activity (27). Evidence in other cell 
types suggests that TUBB3 may be part of a cell survival 
pathway. For instance, its expression level can be modulated by 
different types of cell stress, i.e. hypoxia (anti-VEGFR therapy) 
and nutrient deprivation (28,29). To confirm the interaction 
between ARC and TUBB3, functional studies are needed.
Testing the expression of ERCC1, RRM1 and TUBB3 is 
crucial and necessary before treatment for gemcitabine, cispl-
atin and 5-FU. As known, MSI tumors will not benefit from 
5-FU treatment and, to this analogy, the testing for ERCC1, 
RRM1 and TUBB3 before platinum-based, gemcitabine and 
taxane therapy, respectively. There are a lack of diagnostic 
tests to determine which chemotherapy regimen offers the 
greatest chance for response in an individual patient (18). For 
metastatic CRC, the current treatment paradigm consists of 
5-FU-based regimens in combination with either oxaliplatin 
(FOLFOx) or irinotecan (FOLFIRI), potentially combined 
with therapy targeting either EGFR or VEGFR inhibitor (30). 
Large, prospective clinical trials have shown that the response 
rates for either FOLFOx or FOLFIRI are only approximately 
55% (15). Thus, there is an urgent need for reliable predictive 
markers before therapeutic decision in metastasized CRC.
In conclusion, we found statistically significant correla-
tions between MMR proteins and ERCC1, RRM1 and TUBB3. 
Furthermore, we found a statistically significant correlation 
between the apoptosis repressor protein ARC and RRM1 and 
TUBB3. Taken together, regarding these proteins, there is a 
high therapeutic resistance potential in CRC metastasis. Thus 
we propose to test the known associated predictive proteins, 
before any therapeutic option is offered. Further functional 
studies need to declare the exact regulatory mechanism 
between RRM1, TUBB3 and ARC, as exact relations among 
these proteins cannot be measured by means of immunohis-
tochemistry alone. The assessment of the abovementioned 
markers may be a helpful tool to design chemotherapy proto-
cols for CRC liver metastasis and to define patients who may 
expect a greater clinical benefit. Selection of chemotherapeutic 
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drugs according to their predicted efficacy should be a part 
of future therapeutic decisions and prospective studies. A 
prospective validation of these markers is warranted.
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